ARNA Genomics Develops Blockchain Powered Cancer Research Solution, Announces ICO

Bitcoin has not just revolutionized the global financial system, but it seems to be on its way to changing the healthcare industry as well. ARNA Genomics, a Russian biotechnology company, is demonstrating the potential of blockchain in healthcare with its ARNA Panacea platform.

ARNA Panacea is a clinical trial data analysis and management platform that helps researchers gather, store and analyze drug trial data, especially of those that are used to treat cancer. With the use of blockchain technology, the company has managed to create a potentially unified repository of cancer detection and treatment information from across the world.

It is a well-known fact that cryptocurrency technology brings in higher levels of security, transparency and data integrity to the table. By making use of these very features, ARNA Genomics has created an ecosystem where the observations and results from clinical trials are made available to relevant people from across the world, keeping them updated about the progress in humanity’s fight against cancer.

With the right set of tools, ARNA Panacea enables researchers to maintain their lab notes on the blockchain, complete with timestamp and ownership details etched into it. This very feature also makes collaboration between researchers and their teams easier, allowing them to share ideas and compare notes without feeling threatened about others stealing their ideas or research work.

By encouraging collective, crowd-powered approach to research, ARNA Panacea accelerates the whole process, potentially saving loads of resources and eventually savings plenty of lives. The ARNA Genomics platform also has its own economy driven by ARNA tokens. These tokens can be used to purchase various healthcare services on the platform, including cancer screening and diagnostic tests.

A decentralized universal repository of clinical trials, diagnostic information, disease progression, patient’s performance, etc., can serve as valuable datasets for various analytical and prediction models, which could be integral to cancer research and related studies. ARNA Genomics is now in a position to create just that. With the ARNA Panacea still in development stage, the company has announced the launch of its crowdsale, offering people an opportunity to purchase ARNA tokens.

The ARNA ERC20 compliant tokens are designed to be fixed value cryptocurrency. Token holders will not only be able to spend them on the platform, but they can also hold on to it and use to buy shares in the upcoming ARNA BC company at a low price. ARNA BC will be responsible for selling the company’s DNA Breast Cancer test, which is yet to receive FDA approval.

The ARNA token pre-sale is set to go live on September 21, 2017. The main token sale will follow it on November 19, 2017.